Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM1005 vs Mazdutide in T2DM with Inadequate Glycemic Control
NCT07417306Phase 3Not yet recruiting
- Sponsor
- Huadong Medicine
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of poterepatide in type 2 diabetes mellitus (T2DM), sponsored by Huadong Medicine. Primary endpoint: Change from baseline in Hemoglobin A1c at 40 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
poterepatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07417306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07417306.